A6-4471

A6-4471 is a second-generation small molecule pro-drug inhibitor of the small GTPase ADP-Ribosylation Factor 6 (ARF6). Developed by researchers at the University of Utah and Huntsman Cancer Institute, it is designed to target the unique metabolic dependency of Acute Myeloid Leukemia (AML) cells on ARF6-mediated sphingolipid homeostasis. ARF6 regulates the expression of sphingomyelin synthases (SGMS1 and SGMS2); its inhibition leads to an increased ceramide-to-sphingomyelin ratio. This accumulation of ceramide inhibits the pro-survival AKT pathway, triggering apoptosis in AML cells. Preclinical data indicate that A6-4471 effectively suppresses AML proliferation in vitro and in vivo without significant toxicity to normal hematopoietic cells or host physiology, suggesting a favorable therapeutic window.